Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease.
Diana MendesAhuva AverinMark AtwoodReiko SatoAndrew VyseJames CamplingDerek WeyckerMary P E SlackGillian F EllsburyTendai MugwagwaPublished in: Expert review of pharmacoeconomics & outcomes research (2022)
PCV20 vaccination in adults aged 65-99 years and those aged 18-64 years with underlying comorbidities in England is expected to prevent more hospitalizations, save more lives, and yield lower overall costs than current recommendations for PPV23.